
The life insurance segment of the insurtech sector continues to see less activity than its non-life cousin. Private markets analytics firm Pitchbook’s Q3 2022 Insurtech Report, published just before Christmas, says that $306.5mn of deals were completed in the first three quarters of 2022 in its health and life segment; property and casualty ($518mn) and Commercial ($503mn) represents the two largest segments by dollar amount through Q3 last year.
Insurers are favouring funded re as it helps firms manage the market and longevity risks associated with writing bulk purchase annuity (BPA) business by reducing capital charges and therefore making PRT deals more competitive.
Unsurprisingly, given its growth and potential for capital optimisation, UK regulators have been carefully watching the increased use of funded re. In June 2023, the Prudential Regulatory Authority (PRA) sent a “Dear CRO’ letter to heads of risk at UK life insurers.
The letter outlined the regulator’s two main concerns from a sectoral review which it had carried out.
“One of the key risks arising in funded re is that firms recapture sub-optimal portfolios with depressed values and with limited ability to be transformed effectively to the firms’ preferred portfolio,” the PRA letter said.
Post a comment Cancel reply
Related Posts
Both Demand and Supply Factors Contribute to Rare Secondary Market Pullback in 2024
The life settlement secondary market suffered a rare pull back in aggregate transaction activity in…
Funded Reinsurance Under Scrutiny But Should Remain a Feature of the UK Pension risk Transfer Market
In the past 12 months or so, the Prudential Regulation Authority (PRA), the UK insurance…
Plenty of Guardrails for US Life Insurers Backing Group Annuities With Private Assets
There has been extensive coverage in the trade media in the past 12 months relating…
Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend
The UK government’s Department of Health and Social Care (DHSC) maintains a Mortality Profile for…